Sinntaxis

Is committed to discovering, developing and commercialising novel therapeutics that enhance recovery of brain functions after stroke.

Sinntaxis has an established discovery platform for preclinical studies of stroke recovery, and has filed IP on the use of negative allosteric modulators of the metabotropic glutamate receptor 5 for the treatment of stroke recovery.